Procedimiento para la Implementación Nacional de los Acuerdos
19 mar 2014 Con la base del. Acuerdo del CMDh la Comisión Europea emitirá una “Decisión de. Ejecución”. Medicamentos y. Productos Sanitarios. Page 3. b) ...
vancomycin: CMDh scientific conclusions and grounds for the
De acuerdo con las conclusiones científicas para vancomicina el CMDh considera que el balance beneficio-riesgo del medicamento o medicamentos que
quinapril: CMDh scientific conclusions and grounds for the variation
The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that
paracetamol (IV formulation): CMDh scientific conclusions and
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the
hydrochlorothiazide / spironolactone: CMDh scientific conclusions
De acuerdo con las conclusiones científicas para la hidroclorotiazida/espironolactona el CMDh considera que el balance beneficio-riesgo del medicamento o
Metamizole : CMDh Scientific conclusions and grounds for variation
The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that
vancomycin PSUSA-3097-202001 - CMDh position
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
Valproate: CMDh scientific conclusions and grounds for the variation
28 nov 2021 CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing valproic acid sodium valproate
Ethinylestradiol-Etonogestrel: CMDh scientific conclusions and
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
Fluconazole: CMDh scientific conclusions and grounds for the
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
CMDh - Heads of Medicines Agencies
The CMDh started its activities in November 2005 replacing the informal Mutual Recognition Facilitation Group ( MRFG ) which was in operation over 10
Application for Marketing Authorisation ( MA
CMDh Guidance Document for Submission of Summary of the Pharmacovigilance System CMDh SOP on decision-making process for new active substance status or
[PDF] 31 CMDh update_A Ambrose
2005 – CMDh established under revised Pharmaceutical Legislation (Directive 2001/83/EC) ? 2012 – Responsibilities of CMDh extended
[PDF] Hydrocortisone: CMDh scientific conclusions and grounds for the
Le CMDh approuve les conclusions scientifiques formulées par le PRAC Motifs de la modification des termes de la/des autorisation(s) de mise sur le marché Sur
[PDF] Informations du CMDH - UPR info
Informations du C M D H Sur la situation des droits de l'Homme au Maroc Au titre de Année 2006 - 2007 L'an 2006 et les quatre premiers mois de 2007 se
[PDF] CMDh POSITION PAPER ON THE USE OF QR CODES TO
The provisions detailed in this CMDh paper to provide additional information about the medicinal product through a QR code are also applicable in case the
[PDF] CMDh Best Practice Guide on the processing of - GMP Navigator
1 nov 2020 · CMDh/004/2005 Rev 18 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
[PDF] CMDh-Project for Harmonisation of RMPs (HaRP): Aims and results
PDF Portable Document Format PhV WSP Working Party Pharmacovigilance Work Sharing Procedures Working Party PI Product Information
[PDF] CMDh 399 2019 2019 04 Public consultation - AIFA
CMDh/399/2019 Public consultation 2 3 Recommendations on common regulatory approaches 4 for allergen products 5 Draft 6 Table of Contents
[PDF] CMDh Best Practice Guide on the processing of renewals in the
CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures Table of contents 1 Introduction
Annex I
Scientific conclusions and grounds for the variation to the terms of theMarketing Authorisation(s)
Scientific conclusions
Taking into account the PRAC Assessment Report on the PSUR(s) for vancomycin, the scientific conclusions are as follows: In view of available data on toxic epidermal necrolysis from spontaneous reports, including in somecases a close temporal relationship, a positive de-challenge and/or re-challenge, the PRAC considers a
causal relationship between vancomycin and toxic epidermal necrolysis is at least a reasonable possibility. The PRAC concluded that the product information of products containing vancomycin should be amended accordingly.Update of sections
4.4 and 4.8 of the SmPC to remove a warning on severe bullous reactions. to add a
warning on severe cutaneous adverse reactions, to remove the adverse reaction "Lyell's syndrome" and to add the adverse reaction "toxic epidermal necrolysis" with a frequency of very rare. ThePackage leaflet is updated accordingly.
In view of available data on
acute kidney injury due to interaction between vancomycin and piperacillin/tazobactam from the literature and spontaneous reports, the PRAC considers a causal relationship between vancomycin and acute kidney injury due to interaction between vancomycin and piperacillin/tazobactam is at least a reasonable possibility. The PRAC concluded that the product information of products containing vancomycin for parenteral use should be amended accordingly. Update of sections 4.4 and 4.5 of the SmPC to add a warning on increased risk of acute kidney injury (AKI) with concomitant piperacillin/tazobactam treatment and the interaction. The Package leaflet is updated accordingly. In view of available data on Haemorrhagic Occlusive RetinalVasculitis (HORV) following intracameral
or intravitreal administration from the literature, spontaneous reports and in view of a plausible mechanism of action for both administrations, the PRAC considers a causal relationship between vancomycin and Haemorrhagic Occlusive Retinal Vasculitis (HORV) following intracameral orintravitreal administration is at least a reasonable possibility. The PRAC concluded that the product
information of products containing vancomycin for parenteral use should be amended accordingly. Update of section 4.4 of the SmPC to add a warning on Haemorrhagic Occlusive Retinal Vasculitis (HORV) following intracameral or intravitreal administration. The Package leaflet is updated accordingly. The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s)On the basis of the scientific conclusions for
vancomycin the CMDh is of the opinion that the benefit- risk balance of the medicinal product(s) containing vancomycin is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied.To the extent that additional medi
cinal products containingvancomycin are currently authorised in the EU or are subject to future authorisation procedures in the
EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position. Annex IIAmendments to the
product information of the nationally authorised medicinal product(s) Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold , deleted text strike through)Summary of Product Characteristics
• Section 4.4A warning should be added as follows:
Severe cutaneous adverse reactions (SCARs)
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP), which can be life- threatening or fatal, have been reported in association with vancomycin treatment (see section 4.8). Most of these reactions occurred within a few days and up to eight weeks after commencing treatment with vancomycin. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, vancomycin should be withdrawn immediately and an alternative treatment considered. If the patient has developed a SCAR with the use of vancomycin, treatment with vancomycin must not be restarted at any time.A warning should be removed as follows:
Severe bullous reactions
Stevens-Johnson syndrome (SJS) has been reported with the use of vancomycin (see section 4.8). If symptoms or signs of SJS (e.g. progressive skin rash often with blisters or mucosal lesions) are present, vancomycin treatment should be discontinued immediately and specialised dermatological assessment be sought. A warning for parenteral formulations should be amended as follows:Nephrotoxicity
Vancomycin should be used with care in patients with renal insufficiency, including anuria, as the possibility of developing toxic effects is much higher in the presence of prolonged high blood concentrations. The risk of toxicity is increased by high blood concentrations or prolonged therapy.Regular monitoring of t
he blood levels of vancomycin is indicated in high dose therapy and longer-term use, particularly in patients with renal dysfunction or impaired faculty of hearing as well as in concurrent administration of nephrotoxic or ototoxic substances, respectively (see sections 4.2 and 4.5 A warning for parenteral formulations should be added as follows:Eye disorders
Vancomycin is not authorized for intracameral or intravitreal use, including prophylaxis of endophthalmitis. Hemorrhagic occlusive retinal vasculitis (HORV), including permanent loss of vision, have been observed in individual cases following intracameral or intravitreal use of vancomycin during or after cataract surgery.Section 4.5
For parenteral formulations, "piperacillin/tazobactam" should be added as an example of nephrotoxic interaction, and "(see section 4.4)" should be added at the end of the nephrotoxic interaction description. • Section 4.8Summary of the safety profile
The following should be added:
Severe cutaneous adverse reactions
(SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with vancomycin treatment (see section 4.4).Tabulated list of adverse reactions
The following adverse re
action(s) should be added under the SOCSkin and subcutaneous tissue
disorders with a frequency very rare:Toxic epidermal necrolysis (TEN)
The following adverse reaction(s) should be removed:Lyell's syndrome
Description of selected adverse drug reactions
The following should be deleted:
If a bullous disorder is suspected, the drug should be discontinued and specialised dermatological assessment should be carried out.Package Leaflet
Section 2
- What you need to know before you use vancomycinTaking/using other medicines
Special care is needed if you are taking/using other medicines as some could interact with vancomycin,
for example: For parenteral formulations only, "piperacillin/tazobactam" should be added to the active substances affecting the kidneys.Warnings and precautions
Serious side effects that may lead to loss of vision have been reported following the injection of vancomycin in the eyes. [parenteral formulations only] Talk to your doctor or hospital pharmacist or nurse before using Vancomycin if: You have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking vancomycin. Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic s ymptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with vancomycin treatment. Stop using vancomycin and seek medical attention immediately if you notice any of the symptoms described in section 4.Section 4 - Possible side effects
[start bold]Stop using vancomycin and seek medical attention immediately if you notice any of the following symptoms:[end bold] reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome and toxic epidermal necrolysis). Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome). A red, scaly widespread rash with bumps under the skin and blisters accompanied by fever at the initiation of treatment (acute generalised exanthematous pustulosis).Annex III
Timetable for
the implementation of this positionTimetable for the implementation of this position
Adoption of CMDh position:
October / 2020
CMDh meeting
Transmission to National Competent Authorities
of the translations of the annexes to the position: 29 November 2020Implementation of the position by the Member
States (submission of the variation by the
Marketing Authorisation Holder): 28 January 2021
quotesdbs_dbs35.pdfusesText_40[PDF] edqm
[PDF] type de variation d'amm
[PDF] google gmail
[PDF] googlemail.com se connecter
[PDF] boite mail
[PDF] email hotmail
[PDF] créer un compte gmail
[PDF] gmail sign up
[PDF] compte google
[PDF] exercices pluriel des noms cm2 ? imprimer
[PDF] pluriel des noms en al ce2
[PDF] le pluriel des noms en ou
[PDF] le pluriel des noms en ail
[PDF] exercices pluriel des noms en al ail ou eu